Jul 2 |
Syros Pharmaceuticals: Entering A Decisive Era With An Expected 2024 Phase 3 Readout
|
Jun 17 |
Syros Pharmaceuticals, Inc.'s (NASDAQ:SYRS) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week
|
Jun 13 |
Syros to Host Webcast Event on Higher-Risk Myelodysplastic Syndrome and the Opportunity for Tamibarotene to Become the New Frontline Standard-of-Care for Patients with RARA Gene Overexpression
|
May 15 |
Syros Pharmaceuticals Inc (SYRS) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
May 15 |
Q1 2024 Syros Pharmaceuticals Inc Earnings Call
|
May 14 |
Syros Pharmaceuticals, Inc. (SYRS) Q1 2024 Earnings Call Transcript
|
May 14 |
Syros Pharmaceuticals GAAP EPS of -$0.10 beats by $0.77
|
May 14 |
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
|
May 13 |
Syros Pharmaceuticals Q1 2024 Earnings Preview
|
May 7 |
Syros to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
|